My Covid Vaccine Report Download [REPACK]

As of January 3, 2024, Georgia DPH will be transitioning from the COVID-19 vaccine interactive dashboard to a new weekly report. The weekly report will provide details on COVID-19 vaccination data available to DPH following the end of the Public Health Emergency.

"Receiving the COVID-19 vaccine allowed me to affect change and turn faith into action. I believe the vaccine helps save lives, stabilize our economy, and ensure a safer future for generations to come. I encourage all to take action and be vaccinated."

My Covid Vaccine Report Download

Download File 🔥 https://urloso.com/2y7XMC 🔥

V-safe originally launched in December 2020 to monitor the safety of COVID-19 vaccines and later expanded to include mpox vaccines. Since its launch, 10.1 million V-safe participants completed more than 151 million health surveys about their experiences following COVID-19 and mpox vaccination, and V-safe data have been included in more than 20 scientific publications. V-safe is one of several complementary safety systems CDC uses to closely monitor the safety of vaccines in the United States. It lets vaccine recipients self-report how they feel after receiving a vaccine.

COVID-19 vaccine recommendations have been updated as of October 3, 2023 to add 2023-2024 updated Novavax COVID-19 vaccine. The content on this page will be updated to align with the new recommendations. Learn more.

At the April 19, 2023 meeting of the Advisory Committee on Immunization Practices, CDC presented data related to further analyses of a preliminary safety signal for persons ages 65 years and older who received the updated (bivalent) Pfizer-BioNTech COVID-19 vaccine in one safety monitoring system, the Vaccine Safety Datalink (VSD). Other safety monitoring systems have not observed similar findings. As time has passed and more safety data have accumulated, the initial finding has decreased, and scientists believe factors other than vaccination might have contributed to the initial finding. The current evidence does not support the existence of a safety issue. FDA and CDC will continue to evaluate data as they are available and update the public as needed.

Anaphylaxis after COVID-19 vaccination is rare. It has occurred at a rate of approximately 5 cases per one million vaccine doses administered. Anaphylaxis, a severe type of allergic reaction, can occur after any kind of vaccination. If it happens, healthcare providers can effectively and immediately treat the reaction. Learn more about COVID-19 vaccines and allergic reactions, including anaphylaxis.

Multiple factors contribute to reports of death after COVID-19 vaccination, including heightened public awareness of COVID-19 vaccines, requirements under FDA authorization for COVID-19 vaccines that healthcare providers report any death after COVID-19 vaccination to VAERS (even if it is unclear whether the vaccine was the cause), and reporting requirements in CDC vaccine provider agreements. People receiving COVID-19 vaccines are less likely to die from COVID-19 and its complications and are at no greater risk of death from non-COVID causes, than unvaccinated people.

Similarly, CDC found higher than expected rates of GBS reported to VAERS after J&J/Janssen COVID-19 vaccination but not after mRNA COVID-19 vaccination. These observations contributed to the preferential recommendation by the Advisory Committee on Immunization Practices (ACIP) to use mRNA COVID-19 vaccines over the J&J/Janssen COVID-19 vaccine, which is no longer available in the United States.

Myocarditis and pericarditis after COVID-19 vaccination are rare. Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart. Most patients with myocarditis or pericarditis after COVID-19 vaccination responded well to medicine and rest and felt better quickly, and most cases have been reported after receiving mRNA COVID-19 vaccines.

To date, evidence indicates that the benefits of mRNA COVID-19 vaccination outweigh the risk of myocarditis. CDC and FDA will continue to monitor for and evaluate reports of myocarditis and pericarditis after COVID-19 vaccination. Learn more about myocarditis and pericarditis, including clinical considerations, after mRNA COVID-19 vaccination.

A review of reports indicates a causal relationship between the J&J/Janssen COVID-19 vaccine and TTS. This observation contributed to the preferential recommendation by ACIP to use mRNA COVID-19 vaccines over the J&J/Janssen COVID-19 vaccine, which is no longer available in the United States.

The NYC Health Department's Citywide Immunization Registry (CIR) collects New Yorkers' vaccine records to help ensure that people receive life-saving immunizations, to monitor vaccination rates and to protect public health.

Immunization records are for people born in NYC after 1995 and records for adults who consent to have their vaccinations reported by their health care provider. Providers in NYC must report all COVID-19 and flu vaccinations to the Health Department.

If your record is not found in the CIR (or it contains no immunizations), you should contact your health care provider and ask them to report your immunization history and future immunizations to the CIR. The provider can call the Provider Access Line at 866-692-3641 for more information.

WHO recommends a simplified single-dose regime forprimary immunization for most COVID-19 vaccines which would improve acceptance anduptake and provide adequate protection at a time when most people have had at least oneprior infection.

When monovalent XBB vaccines are not available, any available WHO emergency-uselisted or prequalified vaccine, bivalent variant-containing or monovalent index virusvaccines, may be used since they continue to provide benefits against severe disease inhigh-risk groups.

COVAX aims to accelerate the development and manufacturing of COVID-19 vaccines and guarantee fair and equitable access for every country.COVAX is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and WHO, with UNICEF as a key delivery partner and PAHO as the procurement agent in the Americas.

WHO's EUL procedure is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of these products to people affected by a public health emergency.

SAGE advises WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions.

The draft landscape of COVID-19 vaccine candidates contains information on vaccine candidates collected through public information (e.g. clinical trial registries) and information that were directly provided by vaccine developers to WHO. The landscape is generally updated twice a week, based on the latest information, including those we receive from scientists and research

The proposed attributes and criteria provide considerations for the evaluation and prioritization of COVID-19 candidate vaccines to be considered for further development by WHO. The target audience includes vaccine scientists, product developers, manufacturers, regulators and funding agencies.

WHO has published the target product profiles for COVID-19 vaccines, which describes the preferred and minimally acceptable profiles for human vaccines for long term protection of persons at high ongoing risk of COVID-19, and for reactive use in outbreak settings with rapid onset of immunity. We have also published the criteria for prioritization of vaccines for clinical trials.

To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.

The following charts show the breakdown of people vaccinated, between those who have received only their first vaccine dose, and those who have completed the initial vaccination protocol (2 doses for most vaccines, 1 or 3 for a few manufacturers).

The following chart shows, for each date, the total number of vaccine doses administered in the 12 months preceding that date. This is given per 100 people in the population. All doses, including boosters, are counted individually.

The following chart shows the share of the total population that has received at least one dose of vaccine. This may not equal the share with a complete initial protocol if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

The following chart shows the total number of people that have received at least one dose of the COVID-19 vaccine. This may not equal the number with a complete initial protocol if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

The following chart shows the share of the total population that has completed the initial vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

The following chart shows the total number of people that have completed the initial vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

These charts show the cumulative number of doses donated to the COVAX initiative by different countries, broken down by whether the donations have only been announced, actually donated, or delivered to the recipients. This is only available for a select number of countries for which the COVID-19 Task Force reports the necessary data. 006ab0faaa